AUA/I-PPS Symptom Score Improvement Chart and Q-max Value Improvement
Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST
Late-breaking data from ESMO 2024 suggest ipilimumab / nivolumab may be a new standard of care for non-clear cell renal cell cancer.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
BL-B01D1 shows favorable phase 2 efficacy, safety for urothelial carcinoma
Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
ICI combination rechallenge does not improve outcomes in advanced renal cell carcinoma
Data from the TiNivo-2 trial showed a median progression-free survival of 5.7 months in the tivozanib plus nivolumab arm vs 7.4 months in tivozanib monotherapy arm.
Trial of 67Cu-SAR-bisPSMA in mCRPC progresses through multi-dose cohort
Based on preliminary data, the Safety Review Committee has recommended that the trial proceed with dosing the final 3 patients in the cohort.
